Welcome to our dedicated page for Apnimed news (Ticker: APMD), a resource for investors and traders seeking the latest updates and insights on Apnimed stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Apnimed's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Apnimed's position in the market.
Apnimed (Nasdaq: APMD) priced its upsized initial public offering of 12,000,000 common shares at $16.00 per share, implying expected gross proceeds of $192 million before fees and expenses. The company also granted underwriters a 30-day option to purchase up to 1,800,000 additional shares at the IPO price, less discounts and commissions.
Apnimed common stock is expected to begin trading on the Nasdaq Global Select Market on July 31, 2026 under the ticker “APMD”, with closing anticipated on or about August 3, 2026, subject to customary conditions. All shares are being sold by Apnimed, with BofA Securities, Evercore ISI, Cantor and LifeSci Capital as joint book-running managers.